Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2006

View Archived Issues

XBD-173: clinical anxiolytic effects without benzodiazepine-related adverse events

Phase II evaluation required to establish chemopreventive profile of myoinositol

Sapphire license ghrelin mimetic from Novo Nordisk

Shigamabs shown safe and well tolerated in phase I for E. coli infections

Progenics and Wyeth begin pivotal trials with POI drug candidate

AEterna Zentaris reports new company focus

Somanta and University of Bradford's ICT sign cancer research alliance

StemCells' neural stem cell product enters phase I for Batten disease

ChemGenex begins advanced clinical trials of Ceflatonin for CML

Avidia advances novel IL-6 inhibitor to phase I for Crohn's disease

Access advances towards commercialization of MuGard for oral mucositis

BioDelivery Science expects BEMA-fentanyl NDA filing in Q2 2007

Hospira to acquire Mayne

Endpoints not met in phase II trial with Nucryst's topical cream

Novel agents for treating seizures disclosed in recent Lundbeck patent

Recent Millenia Hope patent reports novel HIV-1 RNase H inhibitors

Novel treatment option for lipoprotein disorders jointly reported by Negma-Lerads and CNRS

Noxafil recommended for approval in Europe

Exenatide gains positive European opinion for the treatment of type 2 diabetes

Merck announces acquisition of Serono

Bionomics reports on novel inhibitors of Kv1.3 for the treatment of multiple sclerosis

Adjunctive estrogen therapy in women with schizophrenia enters phase II study: News in Context

Neurogen and Merck's novel TRPV1 antagonist presented at the ACS meeting

GSK reports on new MCHR1 antagonists for the treatment of obesity

Potent efficacy in vivo of Merck's novel glucagon receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...